HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

An important goal of human immunodeficiency virus (HIV) vaccine design is identification of strategies that elicit effective antiviral humoral immunity. One novel approach comprises priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on virus-like particles....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Virol
Hlavní autoři: Shen, Xiaoying, Basu, Rahul, Sawant, Sheetal, Beaumont, David, Kwa, Sue Fen, LaBranche, Celia, Seaton, Kelly E., Yates, Nicole L., Montefiori, David C., Ferrari, Guido, Wyatt, Linda S., Moss, Bernard, Alam, S. Munir, Haynes, Barton F., Tomaras, Georgia D., Robinson, Harriet L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2017
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5709589/
https://ncbi.nlm.nih.gov/pubmed/29021394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01077-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky